logo
  • About
  • R&D
  • Pipeline
  • Investors
  • News
  • Contact
  • Primary Sclerosing Cholangitis
  • Nonalcoholic Steatohepatitis (NASH)
  • (NASH) דלקת כבד על רקע שומני
Investor Relations

Investor Relations

  • Overview
  • News & Events
    • News
    • Events
    • Presentations
    • Contact IR
    • Email Alerts
  • Financials & Filings
    • SEC Filings
    • Annual Reports
    • Quarterly Results
  • Stock
    • Stock Quote & Chart
    • Historical Stock Price
    • Analyst Coverage
  • Corporate Governance
    • Board Committees
    • Board of Directors
    • Leadership
    • Documents
    • Board Committees

    • Board of Directors

    • Leadership

    • Documents

Documents

  • Regulation FD and Communications Policy
  • Process for Shareholder Communications with the Board of Directors
  • Policy Regarding Shareholder Recommendations of Director Nominees
  • Interested Party Transactions Policy
  • Insider Trading and Blackout Policy
  • Illegal or Unethical Conduct Reporting Procedure
  • Corporate Governance and Nominating Committee Charter
  • Compensation Committee Charter
  • Code of Business Conduct and Ethics
  • Audit Committee Charter
Show 5102550100 per page

Investor Relations

Chemomab Therapeutics Ltd.

Kiryat Atidim, Building 7
Tel Aviv, Israel 6158002

Follow us on

Subscribe to Alerts

Irina Koffler

LifeSci Advisors, LLC

IR@Chemomab.com

Phone: +1-917-734-7387

Barbara Lindheim

Consulting Vice President

Investor & Public Relations

barbara@chemomab.com

Phone: +1-917-355-9234

Copyright © Chemomab. All rights reserved.

Privacy Policy Terms of Service

Designed and built by Studio Praktik